أعلنت شركة ميرك عن عقار جديد لعلاج إلتهاب الكبد الوبائى ( فيروس سى ) ويتكون هذا العقار من تركيبة من عقارين فى قرص واحد من جرازوبريفير/ إلباسفير ( grazoprevir/elbasvir ) .
ومن المنتظر أن تقدم الشركة 14 ملخص لدراسات تقييم النظام العلاجى الجديد فى مؤتمر الكبد الدولى القادم فى فيينا - النمسا والذى سوف يعقد يوم 22 أبريل القادم .
the Regimen has received two new Breakthrough Therapy designations from
the U.S. Food and Drug Administration (FDA) for the treatment of
patients with chronic HCV genotype 4 infection, and for the
treatment of chronic HCV genotype 1 infection in patients
with end stage renal disease on hemodialysis.
A total of 14 abstracts from studies evaluating
grazoprevir/elbasvir are scheduled to be presented in upcoming International Liver Congress in Vienna, Austria April 22 - 28 .
In October 2013, the FDA granted Breakthrough Therapy designation for
grazoprevir/elbasvir for the treatment of patients with chronic HCV
genotype 1 (GT1). In January 2015, the FDA notified Merck of its
intention to rescind that Breakthrough Therapy designation.
The FDA
has now granted two new Breakthrough Therapy designations for
grazoprevir/elbasvir; the designations are now for the treatment of
patients infected with chronic HCV GT1 with end stage renal disease
on hemodialysis, and patients infected with chronic HCV genotype 4
(GT4).